Viatris Inc. VTRS
Composite 44/100; the shares have moved about 32% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 22/100 — a strong mark against it.
Momentum ranks 75/100 — a strong point in its favour. Income ranks 71/100 — a moderate point in its favour. Valuation ranks 66/100 — a moderate point in its favour.
Growth ranks 22/100 — a strong mark against it. Quality ranks 26/100 — a moderate mark against it. Balance-sheet strength ranks 33/100 — a moderate mark against it.
What the company does Viatris Inc. (VTRS) is a global specialty and generic drug manufacturer with four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It produces prescription brand and generic drugs, complex generics, biosimilars, and supports patient care via clinics, seminars, and digital tools across therapeutic areas like cardiovascular, oncology, and diabetes.
Key financials Viatris reports mixed profitability: gross margin 40.3%, operating margin 12.6%, but net margin -2.8%. Revenue declined -3% year-over-year, while ROE is -2.8% and ROCE is -0.3%. Debt/equity stands at 0.96x with net debt/EBITDA at 2.82x, and interest coverage is -0.18x. The dividend yield is 2.8% with a 19.1% payout ratio.
Stock health SideraVista scores Viatris poorly on quality (26.0) and growth (22.5), but favorably on momentum (75.4) and income (71.0). The Piotroski F-Score is 5/9, Altman Z is 1.07, and the current ratio is 1.58. Twelve-month momentum is +67.57%, though it trails the 52-week high by -6.37%.
Price vs fair value VTRS trades at a **discount of 8.30%** to the analyst mean target of 18.50. - Recent industry analysis highlights Viatris among top generic drugmakers (Zacks Industry Outlook). - Momentum has been strong, up 67.57% over 12 months (SideraVista). - Concerns persist over cash flow and leverage amid negative net margins (3 Cash-Producing Stocks That Concern Us).
Looking forward Forward P/E is 6.74x and EV/EBITDA is 12.02x, suggesting a low valuation relative to earnings power. However, weak profitability metrics and high leverage may limit upside without operational improvement. Momentum remains a key positive driver.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.